Severe SpasticityPhase 4SISTERSNCT01032239
SISTERS: Spasticity In Stroke Study - Randomized Study
A Phase 4 study testing intrathecal baclofen in people with Severe Spasticity, run by MedtronicNeuro at 25 sites in 9 countries.
Trial summary
To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who have not reached their therapy goal with other treatment interventions assessed by a… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Severe Spasticity
- What is being tested?
- intrathecal baclofen
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 61 participants
- Where
- 25 sitesin 9 countries
- Study dates
- Nov 2009to Sep 2016
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- To be eligible for inclusion into this study, patients must fulfill all of the following criteria prior to study enrollment:
- patient (or legal guardian) has been informed of the study procedures and has given written informed consent
- patient experienced last stroke > 6 months prior to enrollment
- patient presents spasticity in at least 2 extremities
- patient presents an Ashworth score ≥ 3 in a minimum of two of the affected muscle groups in the lower extremities
- patient is eligible to receive ITB Therapy following the Adult Spasticity Algorithm. A patient does not reach his/her therapy goal with other treatment interventions
Show all 9Show fewer
- stable blood pressure: no change in hypertensive medication in last month (NOTE: ventriculoperitoneal shunts and valves can be present)
- if female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study
- patient/family is willing to comply with study protocol including attending the study visits
Who cannot join
- To be eligible for inclusion in this study the patients must not meet any of the following criteria:
- patient/family is considered by the physician to be unable or unwilling to participate in long-term ITB Therapy management
- patient has known hypersensitivity to baclofen
- active systemic infection (NOTE: pressure sores are not a contraindication unless they are present near the implant sites)
- presence of a cardiac pacemaker, ICD, implantable neurostimulator or drug delivery device
- uncontrolled refractory epilepsy
Show all 9Show fewer
- use of oral vitamin K antagonists, e.g. warfarin/coumadin; unless the patient can switch to another accepted anticoagulant (e.g. heparin, aggrenox, fragmin, plavix, ticlid) for the period of ITB test and implant
- patient is pregnant or breastfeeding
- patient received a Botulinum toxin injection less than 4 months ago
Trial locations and contacts
25 sites in 9 countries.
25 sites in 9 countries
United States9 sites
Saint Alphonsus Regional Med Center
Boise, Idaho, 83704
Design Neuroscience Center
Doral, Florida, 33172
Einstein Hospital/Moss Rehabilitation
Elkins Park, Pennsylvania, 19027-2220
TIRR Memorial Herman Hospital
Houston, Texas, 77030
University of California Irvine
Irvine, California, 92697
Research Medical Center
Kansas City, Missouri, 64132
Rehabilitation Medical Group - Florida Hospital
Orlando, Florida, 32806
Tallahassee Neurological Clinic Department of Neurosurgery
Tallahassee, Florida, 32308
MedStar National Rehabilitation Network
Washington D.C., District of Columbia, 20010
Germany4 sites
Kliniken Beelitz GmbH Neurologische Rehabilitationsklinik
Beelitz-Heilstätten, 14547
Ambulantes Neurologisches Rehabilitationszentrum
Bonn, 53117
Therapiezentrum Burgau
Burgau, 89331
Rhein-Sieg-Klinik Dr. Becker Klinikgesellschaft
Nümbrecht, 51588
Belgium3 sites
Clin. Univ. UCL Saint Luc
Brussels, 1200
Universitair Ziekenhuis Gent
Ghent, 9000
Universitaire Ziekenhuizen Leuven, campus Pellenberg
Leuven, B-3000
Austria2 sites
Sozialmedizinisches Zentrum Baumgartner Höhe Otto-Wagner-Spital
Vienna, 1140
Landeskrankenhaus Hochzirl
Zirl, 6170
Italy2 sites
Centro di Riabilitazione "Villa Beretta"
Costa Masnaga, 23845
Fondazione Salvatore Maugeri Clinica del lavoro e della riabilitazione IRCSS
Pavia, 27100
Spain2 sites
Fundació Privada Institut de Neurorehabilitació Guttmann, Badalona
Barcelona, 08916
Hospital Universitario La Paz
Madrid, 28046
Netherlands1 site
Afdeling Revalidatie Academisch Ziekenhuis Maastricht
Maastricht, 6229
Slovenia1 site
Univerzitetni rehabilitacijski inštitut Republike Slovenije Soča
Ljubljana, 1000
About this study
Official title: A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment
To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who have not reached their therapy goal with other treatment interventions assessed by a decrease in the average Ashworth Scale (AS) score in the lower extremities.
Read the detailed description
This is a randomized, controlled open-label parallel group study to demonstrate the efficacy benefit of ITB Therapy over BMT in post-stroke patients with severe spasticity who have not reached their therapy goal with other treatment interventions.
In order to evaluate the efficacy benefit of ITB Therapy over BMT in post-stroke patients, a two-arm parallel group design will be applied. Patients will be equally randomized to one of two treatment arms:
- ITB Therapy arm; or
- BMT arm
The study consists of a run-in phase of 21 days for the BMT treatment arm and 2-25 days for the ITB Therapy treatment arm, followed by a 6 month active trial.
The BMT treatment arm will receive a combination of oral antispastic medication and physiotherapy. Patients must be prescribed at least one or a combination of the following oral antispastic medications: oral baclofen, tizanidine, diazepam (or other benzodiazepines) or dantrolene. Following the run-in phase, patients will enter the 6 month active trial.
The ITB Therapy treatment arm will receive a combination of ITB Therapy and physiotherapy. During the run-in phase, a test with intrathecal baclofen will be performed to evaluate the response of the patient. Patients fulfilling the test success criterium will be implanted with a Medtronic SynchroMed®II infusion system. Following implant, patients will enter into the 6 month active trial, which includes a 6 week titration phase, during which time oral antispastic medications must be gradually reduced with complete discontinuation by the end of the titration period.
During the 6 month active trial, patients will be assessed at 3 and 6 months. All primary and secondary endpoint assessments will be performed by a blinded assessor.
The total study duration is expected to be 60 months, including a 39 month enrollment period. The total duration per patient is approximately 7 months (approximately 1 month run-in period followed by 6 months active treatment).
- Conditions
- Severe Spasticity
- Being tested
- intrathecal baclofen
- Keywords
- Severe spasticity in post-stroke patients
- Medical subject headings
- Muscle Spasticity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
intrathecal baclofenDrug
ITB test, implant, 6 months follow-up
| Study group | Role | What they receive |
|---|---|---|
| ITB therapy | Active comparator | Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump) Receives: Drug: intrathecal baclofen |
| Best Medical Treatment (BMT) | No intervention | Use one or a combination oral antispastic medication. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6
AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.
Change= AS at month 6 - AS at baseline.
Measured: Baseline and month 6
Secondary outcomes (11)
Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6
AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.
Change= AS at month 6 - AS at baseline.
Measured: Baseline and month 6
Change in Functional Independence Measure (FIM) Score From Baseline to Month 6
FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline.
Measured: Baseline and month 6
Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6
Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline
Measured: Baseline and month 6
Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance
Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated.
Measured: baseline, month 3, month 6
Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6
NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is "no pain" while a score of 10 (ten) is "worst possible pain". Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline.
Measured: Baseline and month 6
Number of Participants Who Achieved Their Primary Therapeutic Goal Assessed With the Goal Attainment Scale (GAS)
GAS is designed to measure the achievement of treatment goals using the following 6 levels of achievement: worse than start (-3), much less than expected (-2), somewhat less than expected (-1), as expected (0), somewhat more than expected (+1), much more than expected (+2). The primary therapy goal and the criteria for the levels of achievement was defined by the medical team together with the patient and his/her family/legal representative/caregiver at the first day of the study. The number and percentage of patients who achieved the therapeutic goal at Month 6 was compared between the ITB and BMT arm.
Measured: month 6
Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6
The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: "no health problems", "moderate health problems", and "severe health problems". Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score.
Measured: Baseline and month 6
Change in SF-12 (12-item Short Form) From Baseline to Month 6
The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline.
Measured: Baseline and month 6
Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6
SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.
Change=SS-QoL score at month 6 - SS-QoL score at baseline.
Measured: Baseline and month 6
Therapy Satisfaction
Patients were presented with two statements ("I am satisfied with the reduction in spasticity provided by my treatment", and "I would recommend this therapy to a friend"). They agreed, disagreed or were neutral with the statements.
Measured: month 6
Healthcare Resource Utilization
Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6
Measured: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Dec 2009 (estimated)
- Study startNov 2009
- Primary completionSep 2016
- Study completionSep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Severe SpasticityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 61 participants (actual)
Sponsor and investigators
- Lead sponsor
- MedtronicNeuro
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Leopold SALTUARI, Prof., Principal investigator, Landeskrankenhaus Hochzirl, Zirl (Austria)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01032239
- Sponsor's protocol ID
- 1.02.7001
- Acronym
- SISTERS
- Status last verified
- Jan 2018
- First submitted
- 7 Dec 2009
- Last updated
- 15 Feb 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Calabrese A, Saltuari L. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. Stroke. 2018 Sep;49(9):2129-2137. doi: 10.1161/STROKEAHA.118.022255.
PubMed 30354975Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Berthuy N, Calabrese A, Loven M, Saltuari L. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650. doi: 10.1136/jnnp-2017-317021. Epub 2018 Jan 11.
PubMed 29326296
Study at a glance
From the registry record, last updated by the sponsor on 15 Feb 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment
- ClinicalTrials.gov ID
- NCT01032239
- Acronym / sponsor ID
- SISTERS / 1.02.7001
- Conditions
- Severe Spasticity
- Keywords
- Severe spasticity in post-stroke patients
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 61 participants (actual)
- Lead sponsor
- MedtronicNeuroIndustry (pharma, biotech, devices)
- Study start
- Nov 2009
- Primary completion
- Sep 2016 (actual)
- Study completion
- Sep 2016 (actual)
- First posted
- 15 Dec 2009 (estimated)
- Results
- Posted 15 Feb 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who have not reached their therapy goal with other treatment interventions assessed by a decrease in the average Ashworth Scale (AS) score in the lower extremities.
Detailed description
This is a randomized, controlled open-label parallel group study to demonstrate the efficacy benefit of ITB Therapy over BMT in post-stroke patients with severe spasticity who have not reached their therapy goal with other treatment interventions.
In order to evaluate the efficacy benefit of ITB Therapy over BMT in post-stroke patients, a two-arm parallel group design will be applied. Patients will be equally randomized to one of two treatment arms:
- ITB Therapy arm; or
- BMT arm
The study consists of a run-in phase of 21 days for the BMT treatment arm and 2-25 days for the ITB Therapy treatment arm, followed by a 6 month active trial.
The BMT treatment arm will receive a combination of oral antispastic medication and physiotherapy. Patients must be prescribed at least one or a combination of the following oral antispastic medications: oral baclofen, tizanidine, diazepam (or other benzodiazepines) or dantrolene. Following the run-in phase, patients will enter the 6 month active trial.
The ITB Therapy treatment arm will receive a combination of ITB Therapy and physiotherapy. During the run-in phase, a test with intrathecal baclofen will be performed to evaluate the response of the patient. Patients fulfilling the test success criterium will be implanted with a Medtronic SynchroMed®II infusion system. Following implant, patients will enter into the 6 month active trial, which includes a 6 week titration phase, during which time oral antispastic medications must be gradually reduced with complete discontinuation by the end of the titration period.
During the 6 month active trial, patients will be assessed at 3 and 6 months. All primary and secondary endpoint assessments will be performed by a blinded assessor.
The total study duration is expected to be 60 months, including a 39 month enrollment period. The total duration per patient is approximately 7 months (approximately 1 month run-in period followed by 6 months active treatment).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ITB therapy | Active comparator | Drug: intrathecal baclofenIntrathecal Baclofen therapy (Intrathecal baclofen + implantable pump) |
| Best Medical Treatment (BMT) | No intervention | –Use one or a combination oral antispastic medication. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- To be eligible for inclusion into this study, patients must fulfill all of the following criteria prior to study enrollment:
- patient (or legal guardian) has been informed of the study procedures and has given written informed consent
- patient experienced last stroke > 6 months prior to enrollment
- patient presents spasticity in at least 2 extremities
- patient presents an Ashworth score ≥ 3 in a minimum of two of the affected muscle groups in the lower extremities
Key exclusion criteria (9 listed)
- To be eligible for inclusion in this study the patients must not meet any of the following criteria:
- patient/family is considered by the physician to be unable or unwilling to participate in long-term ITB Therapy management
- patient has known hypersensitivity to baclofen
- active systemic infection (NOTE: pressure sores are not a contraindication unless they are present near the implant sites)
- presence of a cardiac pacemaker, ICD, implantable neurostimulator or drug delivery device
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| intrathecal baclofenITB test, implant, 6 months follow-up | Drug | ITB therapy |
Primary outcome
Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6
Time frame: Baseline and month 6
AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed. Change= AS at month 6 - AS at baseline.
11 secondary outcomes
Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6
Time frame: Baseline and month 6
Change in Functional Independence Measure (FIM) Score From Baseline to Month 6
Time frame: Baseline and month 6
Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6
Time frame: Baseline and month 6
Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance
Time frame: baseline, month 3, month 6
Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6
Time frame: Baseline and month 6
Number of Participants Who Achieved Their Primary Therapeutic Goal Assessed With the Goal Attainment Scale (GAS)
Time frame: month 6
Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6
Time frame: Baseline and month 6
Change in SF-12 (12-item Short Form) From Baseline to Month 6
Time frame: Baseline and month 6
Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6
Time frame: Baseline and month 6
Therapy Satisfaction
Time frame: month 6
Healthcare Resource Utilization
Time frame: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Feb 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 30354975Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Calabrese A, Saltuari L. Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. Stroke. 2018 Sep;49(9):2129-2137. doi: 10.1161/STROKEAHA.118.022255.
- Derived from this study: PubMed 29326296Creamer M, Cloud G, Kossmehl P, Yochelson M, Francisco GE, Ward AB, Wissel J, Zampolini M, Abouihia A, Berthuy N, Calabrese A, Loven M, Saltuari L. Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry. 2018 Jun;89(6):642-650. doi: 10.1136/jnnp-2017-317021. Epub 2018 Jan 11.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leopold SALTUARI, Prof. principal investigator
Landeskrankenhaus Hochzirl, Zirl (Austria)
25 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing intrathecal baclofen in people with Severe Spasticity, run by MedtronicNeuro at 25 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 25 sites in United States, Germany, Belgium, Austria, Italy and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Feb 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 (time frame: Baseline and month 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01032239, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2018; AzTrials last refreshed its copy on 27 Oct 2026.